Acrivon Therapeutics Inc (ACRV)
9.59
+1.13
(+13.36%)
USD |
NASDAQ |
May 03, 16:00
9.50
-0.09
(-0.94%)
After-Hours: 20:00
Acrivon Therapeutics Cash from Operations (TTM): -42.64M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -42.64M |
| September 30, 2023 | -39.63M |
| June 30, 2023 | -36.34M |
| Date | Value |
|---|---|
| March 31, 2023 | -33.06M |
| December 31, 2022 | -30.12M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-42.64M
Minimum
Dec 2023
-30.12M
Maximum
Dec 2022
-36.36M
Average
-36.34M
Median
Jun 2023
Cash from Operations (TTM) Benchmarks
| MyMD Pharmaceuticals Inc | -12.98M |
| Vincerx Pharma Inc | -40.45M |
| GlycoMimetics Inc | -34.88M |
| Immunic Inc | -70.83M |
| Skye Bioscience Inc | -13.95M |